To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05853965
Title Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma (BELI(E)VE)
Acronym BELI(E)VE
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Universitätsklinikum Hamburg-Eppendorf
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
University Medical Center Hamburg-Eppendorf RECRUITING Hamburg Ham 20246 Germany Details
Klinikum Chemnitz RECRUITING Chemnitz Germany Details
Uniklinik Heidelberg RECRUITING Heidelberg Germany Details
UKSH Lübeck RECRUITING Lübeck Germany Details
Uniklinkum Ulm RECRUITING Ulm Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field